YARW
Yarrow Bioscience Inc
YARW | NASDAQ
$19.90
-$0.10 (-0.50%)
At close: Oct 30, 2026, 4:00 PM ET
$19.90
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 7:30 PM ET
Company Profile
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
Key Executives
| Name | Position |
|---|---|
| Rebecca Velez Frey | Chief Executive Officer, President & Director |
| Rachael Alford | Chief Operating Officer |
| Tyler Zeronda | Chief Financial Officer |
| Lori Payton | Chief Development Officer |
| Steven W. Ryder | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 17, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 14, 2026 | 8-K | Current Report |
| Sep 11, 2026 | 424B5 | Filing |
| Sep 11, 2026 | 424B5 | Filing |
| Sep 10, 2026 | 8-K | Current Report |
| Aug 19, 2026 | EFFECT | Filing |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 14, 2026 | POS AM | Filing |
| Aug 13, 2026 | 8-K/A | [Amend] Current Report |
Yarrow Bioscience Inc
YARW
| Country | United States |
| IPO Date | Jul 28, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Rebecca Velez Frey |
Contact Details
470 James Street, Suite 007 New Haven,
Connecticut 06513 United States
Stock Details
| Ticker Symbol | YARW |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001566044 |
| CUSIP Number | 92941V407 |
| ISIN Number | US92941V4077 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove YARW